Abstract:Background: In the OlympiAD study, olaparib showed a clinically meaningful benefit in progression-free survival compared with chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and HER2-negative metastatic breast cancer (mBC; Robson N Engl J Med 2017). Final prespecified median overall survival (OS) at 64% data maturity was 19.3 months with olaparib versus 17.1 months with TPC (Robson Ann Oncol 2019). At this time, 26 patients continued to receive olaparib, with none continuing to receive TPC as assigned. After consenting to a protocol amendment, post hoc follow-up of patients for survival status and serious adverse events continued. Patients and methods: OlympiAD is a Phase III, randomized, controlled, open-label trial (NCT02000622). Patients with a germline BRCAm and HER2-negative mBC who had received ≤2 prior lines of chemotherapy for mBC were randomized to olaparib tablets (300 mg twice daily) or predeclared TPC (capecitabine, vinorelbine or eribulin). Extended OS and safety follow-up were exploratory endpoints; the study was not powered to detect an OS benefit or treatment effect between subgroups. The overall hazard ratio (HR) was estimated using a stratified log-rank test, and a single Cox proportional hazards model was used for analyses in prespecified subgroups. Results: Of patients randomized to olaparib (n=205) or TPC (n=97), 160 (78.0%) and 80 patients (82.5%) respectively had withdrawn from the study (majority due to death), and seven and eight patients, respectively, did not participate in the extended follow-up. At data cut-off (March 3, 2019), 223 patients had died (73.8% data maturity), 24 (11.7%) patients from the olaparib arm and nine patients (9.3%) from the TPC arm were continuing the study off treatment, no patients were continuing to receive TPC as assigned. Fourteen patients (6.8%) were continuing olaparib at this time; in this small number of patients at baseline their median age was 42.5 years, 42.9% had not received prior chemotherapy for mBC, 57.1% were TNBC, 50.0% had a BRCA1 mutation, 42.9% had liver metastasis and 57.1% had ≥2 metastatic sites. Median follow-up was 18.9 months in the olaparib arm and 15.5 months in the TPC arm (40.7 and 29.2 months in censored patients, respectively). OS and landmark analyses for the overall population and prespecified key subgroups are reported in the Table. Of patients who discontinued study treatment, 2.0% in the olaparib arm and 11.3% in the TPC arm received subsequent PARP inhibitors, and 42.4% and 48.5%, respectively, received subsequent platinum chemotherapy. Median total study treatment duration was 251 days in the olaparib arm versus 105 days in the TPC arm, with 8.8% of olaparib patients receiving treatment for >3 years versus no TPC patients. During the extended follow-up period, there were no new serious adverse events suspected to be related to olaparib treatment, including no reports of myelodysplastic syndrome/acute myeloid leukemia. Conclusions: Total treatment duration was more than double for olaparib versus TPC, with no new safety findings over long-term treatment. With extended follow-up, OS did not differ significantly between treatment arms; however, continued OS benefit was suggested for olaparib versus chemotherapy for patients in the first-line setting for mBC. Citation Format: Mark Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong, Wendy Bannister, Carsten Goessl, Allison Allen, Pierfranco Conte. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD4-03.

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

Overall Survival (OS) in Patients with Platinum-Sensitive Relapsed Ovarian Cancer (PSROC) Treated with Olaparib Maintenance Monotherapy: Update from the L-MOCA Trial.

PR072/#1519 Effort: Clinical and Molecular Features Associated with Clinical Benefit from Adavosertib with or Without Olaparib in Recurrent Ovarian Cancer Following Progression on PARP Inhibition (NCT03579316)

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Olaparib Maintenance Monotherapy in Chinese Patients with Platinum‐sensitive Relapsed Ovarian Cancer: China Cohort from the Phase III SOLO2 Trial

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Olaparib Maintenance Therapy in Patients (pts) with a BRCA1 And/or BRCA2 Mutation (brcam) and Newly Diagnosed Advanced Ovarian Cancer (OC): SOLO1 China Cohort

Abstract PD11-12: PD11-12 DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC)

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

L-MOCA: An open-label study of olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer.

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).

Abstract PD4-03: OlympiAD Extended Follow-Up for Overall Survival and Safety: Olaparib Versus Chemotherapy Treatment of Physician’s Choice in Patients with a Germline BRCA Mutation and HER2-negative Metastatic Breast Cancer

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer